Yazar "Demir, Mehmet" seçeneğine göre listele

Listeleniyor 1 - 20 / 34
  • Küçük Resim
    Öğe
    Characterization of electrodeposited Ni-Cr/hBN composite coatings
    (Elsevier Science Sa, 2020) Demir, Mehmet; Kanca, Erdogan; Karahan, Ismail Hakki
    In this study, Ni-Cr/hBN composite coatings with different hBN content were deposited on AISI 1040 mild carbon steel using electrodeposition. The coatings were characterized using scanning electron microscopy (SEM), energy dispersive spectroscopy (EDS), X-ray diffractometry (XRD), cyclic voltammetry (CV), 2D surface profilometery, nano-indentation, corrosion and wear tests. While some cracks were observed in the Ni-Cr alloy coatings, more compact and crack-free surfaces were obtained in the Ni-Cr/hBN composite coatings under all deposition conditions. XRD analysis of the Ni-Cr/hBN layer revealed the presence of a predominant Ni phase with Cr, Cr2Ni3B6, (Ni2Cr23)(0.16), and hBN phases in the structure. Depending on deposition parameters, the microhardness and nanohardness of the Ni-Cr and Ni-Cr/hBN coatings were found to range between 308 and 538 HV and 1,86-7,69 GPa respectively. hBN acted as a solid lubricant in the wear tests; the friction coefficient decreased and wear resistance was improved. Among the composite coatings, the corrosion resistance of the coating with 20 g/l hBN was found to be 12 and 3.3 times higher than the steel substrate and Ni-Cr alloy, respectively. The hBN additive provided better mechanical properties and corrosion resistance in the range of 5-20 g/l hBN, but after 20 g/l hBN agglomeration became a problem and impaired the mechanical properties. The highest corrosion and abrasion resistance was obtained with 20 g/l hBN. (c) 2020 Elsevier B.V. All rights reserved.
  • Küçük Resim
    Öğe
    Colonoscope incarceration in an inguinal hernia: a complication of colonoscopy
    (Georg Thieme Verlag Kg, 2015) Tas, Adnan; Oruc, Cem; Olmez, Sehmus; Sahan, Mustafa; Ugur, Mustafa; Hakimoglu, Sedat; Demir, Mehmet
    [Abstract Not Available]
  • Küçük Resim
    Öğe
    Demographic Characteristics and Transmission Risk Factors of Patients with Hepatitis C Virus in Turkey: The EPI-C, A Multicenter and Cross-sectional Trial
    (2021) Tabak, Fehmi; Şirin, Göktuğ; Demir, Mehmet; Aladağ, Murat; Sümer, Şua; Kurtaran, Behice; Tosun, Selma
    Objectives: To describe the prevalence of risk factors in patients infected with hepatitis C virus (HCV). Materials and Methods: Patients who were aged >18 years visiting outpatient clinics and diagnosed as having HCV infection were enrolled in this cross-sectional, multicenter study conducted in 71 cities. Patient data on socio-demographic and clinical characteristics and pre-defined risk factors were collected. Results: Among 1,018 patients, 53.0% were women. The mean age was 57.2±14.3 years and 34.8% had been diagnosed as having HCV infection >10 years before enrollment. Almost half of the patients (45.5%) were diagnosed during their regular check-up visits, and only 16.8% were diagnosed because of signs or symptoms of HCV. Genotype 1 and sub-genotype 1 b were detected in 87.9% and 73.7% of the patients, respectively. At least one risk factor was present in 94.8% of the patients. The most frequently reported risk factor was major dental procedures (79.2%), followed by major surgical operations (56.9%) and minor surgical interventions (42.3%). Conclusion: Our results revealed that most of the patients with HCV infection underwent major dental procedures
  • Küçük Resim
    Öğe
    Differences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis B
    (2015) Koklu, Seyfettin; Gulsen, Murat Taner; Tuna, Yasar; Koklu, Hayretdin; Yuksel, Osman; Demir, Mehmet; Guner, Rahmet
    Summary Background Results are conflicting with respect to the renal effects of anti-viral agents used for hepatitis B virus infection. Aim To compare short and long-term renal effects in real-life settings and to determine risk factors for renal impairment during treatment. Methods 2221 treatment-naïve patients were enrolled. Among these, 895 (302 lamivudine, 27 telbivudine, 282 entecavir, 273 tenofovir and 11 adefovir initiated patients) had 'repeated measures' of creatinine (baseline, 1st, 6th, 12th and 24th month of treatment). Telbivudine and adefovir groups were excluded from further analysis because of the low number of patients. We calculated the glomerular filtration rate (GFR) using the Modification of Diet in Renal Disease (MDRD) formula at each time point. Hypophosphataemia was also recorded. Risk factors for renal impairment were analysed. Results Tenofovir caused a decline in GFR at each time point when compared to baseline levels. However, lamivudine and entecavir did not change GFR. GFR-shifting from ?90 to 60-89 mL/min/1.73 m2 was comparable among groups. The proportion of patients whose baseline creatinine increased more than 25% was comparable among all anti-virals. GFR showed a decline in patients who switched from entecavir to tenofovir. One patient with compensated cirrhosis needed to change from tenofovir because of renal safety. Seven and three patients developed transient hypophosphataemia in the tenofovir and lamivudine groups, respectively. Conclusions Although tenofovir caused a decline in GFR, differences between the anti-viral agents do not appear to be so impressive. In patients with and without renal risk factors at baseline, there is no impact of anti-virals, including tenofovir. © 2014 John Wiley & Sons Ltd.
  • [ N/A ]
    Öğe
  • Küçük Resim
    Öğe
    Effect of saccharin addition on formation, wear and corrosion resistance of electrodeposited Ni-Cr coatings
    (Sciendo, 2023) Demir, Mehmet; Kanca, Erdogan; Karahan, Ismail Hakki
    Numerous factors play a pivotal role in shaping the mechanical and corrosion resistance properties of electrodeposited Ni-Cr alloy coatings. This study delves into the deposition of Ni-Cr alloy coatings on AISI 1040 steel, examining the influence of saccharin additives within the electrodeposition bath. Specifically, the concentration of saccharin within the solution was varied over a range of 0 to 2 g/l. Following the electrodeposition process, a comprehensive array of characterization techniques was employed, encompassing 2D surface roughness analysis, scanning electron microscopy, X-ray diffraction, nanoindentation, energy-dispersive X-ray spectroscopy and assessments of wear and corrosion performance. The characterization results of this article reveal a compelling difference between saccharin-free Ni-Cr coatings and their saccharin-modified counterparts. Notably, microcracks, a common occurrence in saccharin-free coatings, were suppressed in the saccharin-modified Ni-Cr coatings. Additionally, the latter exhibited a smoother and more uniform surface texture. A crucial observation was that the introduction of saccharin into the bath was directly associated with an increased incorporation of chromium within the coatings, resulting in higher nanohardness values. Furthermore, the residual stress within the coatings shifted from tensile to compression as saccharin concentrations increased. Concurrently, surface roughness and wear rates exhibited a consistent downward trend with increasing saccharin concentrations in the solution. The most significant findings were seen in the domain of corrosion resistance. Saccharin-modified Ni-Cr coatings outperformed the bare steel substrate and saccharin-free Ni-Cr coatings. Intriguingly, the enhancement of corrosion resistance was not linearly proportional to saccharin concentration; the optimal corrosion resistance was achieved at a concentration of 1 g/l.
  • Küçük Resim
    Öğe
    The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort
    (Kare Publ, 2023) Yaras, Serkan; Demir, Mehmet; Barutcu, Sezgin; Yildirim, Abdullah Emre; Gurel, Selim; Ucbilek, Enver; Kurtulmus, Ilkce Akgun
    Background and Aim: The aims of the present study were to evaluate the real-life efficacy and tolerability of glecaprevir (GLE)/pibrentasvir (PIB) in the treatment of patients with chronic hepatitis C (CHC).Materials and Methods: Between May 2019 and May 2022, 686 patients with CHC, treated with GLE/PIB combination from 21 participating centers in Turkiye, were enrolled in the study.Results: All patients were Caucasian, and their median age was 56 years. At the start of GLE/PIB treatment, the median serum Hepatitis C virus RNA and serum alanine amino transaminase (ALT) levels were 6.74 log10 IU/mL and 47 U/L, respectively. Fifty-three percent of the patients were infected with genotype 1b, followed by genotype 3 (17%). Diabetes was the more common concomitant disease. The sustained virological response (SVR12) was 91.4% with intent-to-treat analysis and 98.5% with per protocol analysis. The SVR12 rates were statistically significant differences between the patients who were i.v. drug users and non-user (88.0% vs. 98.8%, p=0.025). From the baseline to SVR12, the serum ALT levels and Model for End-Stage Liver Disease score were significantly improved (p<0.001 and p=0.014, respectively). No severe adverse effect was observed.Conclusion: GLE/PIB is an effective and tolerable treatment in patients with CHC.
  • [ N/A ]
    Öğe
    Etiology of Cirrhosis in Turkey: A National Cohort Study
    (Elsevier, 2021) Yildirim, Abdullah Emre; Ucbilek, Enver; Oruncu, M. Berk; Turan, Ilker; Demir, Mehmet; Koksal, Aydin; Uyanikoglu, Ahmet
    [Abstract Not Available]
  • Küçük Resim
    Öğe
    Fragmented QRS is an independent predictor of mortality in patients with decompensated cirrhosis
    (Wiley-Blackwell, 2014) Demir, Mehmet
    [Abstract Not Available]
  • Küçük Resim
    Öğe
    Fragmented QRS is associated with cirrhotic cardiomyopathy in patients with decompensated cirrhosis
    (Univ Catholique Louvain-Ucl, 2016) Demir, Mehmet; Kurt, Mustafa; Akcay, Adnan Burak
    Background/Aim : It has been reported that the fragmented QRS (fQRS) is related to left ventricular systolic dysfunction and diastolic dysfunction. The aim of this study was to determine the frequency of fragmented QRS (fQRS) in patients with decompensated cirrhosis and to evaluate the relationship between the presence of fQRS and systolic and diastolic dysfunction. Methods : The study included consecutive 189 patients with decompensated cirrhosis. fQRS pattern was described as presence of RSR' manifested as existence of additional R wave and notching in either R or S waves in ECG recordings. Conventional echocardiography and tissue doppler echocardiography were performed in all patients. Results : The prevalence of fQRS was 31% (59/189) in patients with decompensated cirrhosis. The patients with fQRS had worse diastolic and systolic functions in comparison to the patients without fQRS. In addition, multivariate analysis revealed that the presence of an fQRS, Na levels < 125 mEq/L, the Child-Pugh score and the MELD score were independent predictive factors for mortality (respectively, p < 0.001, p < 0.001, p < 0.001 and p < 0.001). Conclusions : In conclusion, this study showed a relationship between the presence of an fQRS and cardiac dysfunction. In addition, the fQRS appeared to act as an independent predictor of mortality in patients with decompensated cirrhosis. These data suggest that the fQRS may represent a novel noninvasive marker for cardiac involvement and for predicting mortality in patients with decompensated cirrhosis.
  • Küçük Resim
    Öğe
    Genotype distribution of Hepatitis C Virus in Hatay province of Turkey
    (Galenos Yayınevi, 2020) Çabalak, Mehmet; Bal, Tayibe; Demir, Mehmet; Ocak, Sabahattin; Önlen, Yusuf
    Objectives: The treatment duration and response of chronic hepatitis C (CHC) are closely related to the genotypes of hepatitis C virus (HCV). This study aimed to determine the genotype distributions among CHC patients in the Hatay province of Turkey. Materials and Methods: In this study, demographic data of 589 patients who received a therapy for CHC at the infectious diseases and gastroenterology clinics between June 2016 and May 2019 were retrieved from the hospital information system and medical charts of the patients and were retrospectively reviewed. Results: The most common HCV genotype in our study was genotype 1b (66.9%), followed by genotype 2 (10.5%), genotype 1a (7.3%), genotype 4 (7.1%), genotype 3 (7%), and mixed genotype (1.2%). Six of the mixed genotypes were identified as 1b+4, while one was 1a+3. There was a statistically significant difference between females and males with regards to the HCV genotypes (p<0.001). Patients with genotype 1b tended to be older, while patients with genotypes 3 and 4 tended to be younger. Conclusion: Genotype 1b is the most common HCV genotype in Hatay province, and it is followed by genotypes 2, 1a, 4 and 3. Compared to the studies conducted in previous years in Turkey, our study identified a lower rate for genotype 1b, along with an increase in the distribution rates of the other genotypes. Monitoring the changes in HCV genotype distribution is of vital importance to develop effective strategies in the treatment of HCV
  • Küçük Resim
    Öğe
    Hepatitis C virus genotypes in Adana and Antakya regions of Turkey*
    (2014) Öztürk, Agah Bahadır; Doğan, Ümit Bilge; Öztürk Akçaer, Nevin; Özyazıcı, Gonca; Demir, Mehmet; Akın, Mustafa Salih; Bingöl, Ali Süha
    Background/aim: Hepatitis C virus (HCV) genotype 1 was found to be dominant in Turkey. In this study, HCV genotypes were examined in the Adana and Antakya regions of Turkey. Materials and methods: The study consisted of 639 HCV-RNA–positive patients with chronic HCV infection in Adana (214 males and 101 females) and Antakya (139 males and 185 females) in Turkey. Real time-polymerase chain reaction was used for genotype determination. Results: In Antakya, it was determined that the percentages of genotypes of type 1a (0.31%), 1b (86.73%), 2 (9.26%), 3 (0.93%), and 4 (2.78%) were compatible with the nationwide results seen in Turkey. In Adana, the percentages of genotypes of type 1a (3.49%), 1b (55.24%), 2 (14.60%), 3 (26.03%), and 4 (0.63%) were found to be different. This difference was mainly due to the infection rates in males: genotype 1b was significantly lower (42.5% versus 82.2%, P < 0.001) in men in Adana, but genotype 2 (17.8% versus 7.9%, P = 0.021) and genotype 3 (34.6% versus 7.9%, P < 0.001) were significantly higher in men than in women in Adana. Conclusion: Rates of genotypes 2 and 3 were unexpectedly high in Adana compared to other parts of Turkey
  • [ N/A ]
    Öğe
    High dose oral furosemide with salt ingestion in the treatment of refractory ascites of liver cirrhosis
    (The Canadian Society for Clinical Investigation, 2016) Yakar, Tolga; Demir, Mehmet; Dogan, Ozlem; Parlakgumus, Alper; Ozer, Birol; Serin, Ender
    Purpose: We aimed to evaluate and compare the efficacy and safety of high-dose furosemide+salt orally by comparing HSS+ furosemide (i.v.) and repeated paracentesis in patients with RA. Methods: This was a prospective study of 78 cirrhotic patients with RA, randomized into three groups: Group A (n= 25) i.v. furosemide (200-300 mg bid) and 3% hypotonic saline solution (HSS) (once or twice a day); Group B (n= 26) oral furosemide tablets (360-520 mg bid) and salt (2.5 g bid); and, Group C (n= 27) repeated large-volume-paracentesis (RLVP) with albumin infusion. Patients without hyperkalemia were administrated 100 mg of spironolactone/day. During the follow-up; INR, creatinine, and total bilirubin levels were measured to determine the change in MELD (model of end stage liver disease) score. Results: Hepatic encephalopathy (HE), severe episodes of spontaneous bacterial peritonitis (SBP) and pleural effusions (PE) occurred more frequently in Group C. Improvement in Child-Pugh and MELD score was better in Group A and B than Group C. In Group B, improvements were seen in the Child-Pugh and MELD score, reduction in body weight, duration and number of hospitalization. In Groups A and B, remarkable increases in diuresis were observed (706±116 to 2425±633 mL and 691±111 to 2405±772 mL) and serum sodium levels also improved. HE and SBP were occurred more often in group C (p<0.002). Hospitalization decreased significantly in Group B (p<0.001). There was no significant difference in survival among groups. Conclusion: High dose oral furosemide with salt ingestion may be an alternative, effective, safe and well-tolerated method of therapy for RA. © 2016 CIM.
  • [ N/A ]
    Öğe
    High Dose Oral Furosemide with Salt Ingestion in the Treatment of Refractory Ascites of Liver Cirrhosis
    (Canadian Soc Clinical Investigation, 2016) Yakar, Tolga; Demir, Mehmet; Dogan, Ozlem; Parlakgumus, Alper; Ozer, Birol; Serin, Ender
    Purpose: We aimed to evaluate and compare the efficacy and safety of high-dose furosemide+salt orally by comparing HSS+furosemide (i.v.) and repeated paracentesis in patients with RA. Methods: This was a prospective study of 78 cirrhotic patients with RA, randomized into three groups: Group A (n=25) i.v. furosemide (200-300 mg bid) and 3% hypotonic saline solution (HSS) (once or twice a day); Group B (n= 26) oral furosemide tablets (360-520 mg bid) and salt (2.5 g bid); and, Group C (n= 27) repeated large-volume-paracentesis (RLVP) with albumin infusion. Patients without hyperkalemia were administrated 100 mg of spironolactone/day. During the follow-up; INR, creatinine, and total bilirubin levels were measured to determine the change in MELD (model of end stage liver disease) score. Results: Hepatic encephalopathy (HE), severe episodes of spontaneous bacterial peritonitis (SBP) and pleural effusions (PE) occurred more frequently in Group C. Improvement in Child-Pugh and MELD score was better in Group A and B than Group C. In Group B, improvements were seen in the Child-Pugh and MELD score, reduction in body weight, duration and number of hospitalization. In Groups A and B, remarkable increases in diuresis were observed (706 +/- 116 to 2425 +/- 633 mL and 691 +/- 111 to 2405 +/- 772 mL) and serum sodium levels also improved. HE and SBP were occurred more often in group C (p< 0.002). Hospitalization decreased significantly in Group B (p< 0.001). There was no significant difference in survival among groups. Conclusion: High dose oral furosemide with salt ingestion may be an alternative, effective, safe and well-tolerated method of therapy for RA.
  • [ N/A ]
    Öğe
    High Dose Oral Furosemide With Salt Ingestion In The Treatment Of Refractory Ascites Of Liver Cirrhosis
    (The Canadian Society for Clinical Investigation, 2016) Yakar, Tolga; Demir, Mehmet; Dogan, Ozlem; Parlakgumus, Alper; Ozer, Birol; Serin, Ender
    Purpose: We aimed to evaluate and compare the efficacy and safety of high-dose furosemide+salt orally by comparing HSS+ furosemide (i.v.) and repeated paracentesis in patients with RA. Methods: This was a prospective study of 78 cirrhotic patients with RA, randomized into three groups: Group A (n= 25) i.v. furosemide (200-300 mg bid) and 3% hypotonic saline solution (HSS) (once or twice a day); Group B (n= 26) oral furosemide tablets (360-520 mg bid) and salt (2.5 g bid); and, Group C (n= 27) repeated large-volume-paracentesis (RLVP) with albumin infusion. Patients without hyperkalemia were administrated 100 mg of spironolactone/day. During the follow-up; INR, creatinine, and total bilirubin levels were measured to determine the change in MELD (model of end stage liver disease) score. Results: Hepatic encephalopathy (HE), severe episodes of spontaneous bacterial peritonitis (SBP) and pleural effusions (PE) occurred more frequently in Group C. Improvement in Child-Pugh and MELD score was better in Group A and B than Group C. In Group B, improvements were seen in the Child-Pugh and MELD score, reduction in body weight, duration and number of hospitalization. In Groups A and B, remarkable increases in diuresis were observed (706±116 to 2425±633 mL and 691±111 to 2405±772 mL) and serum sodium levels also improved. HE and SBP were occurred more often in group C (p<0.002). Hospitalization decreased significantly in Group B (p<0.001). There was no significant difference in survival among groups. Conclusion: High dose oral furosemide with salt ingestion may be an alternative, effective, safe and well-tolerated method of therapy for RA © 2016. Clinical and Investigative Medicine. All Rights Reserved.
  • Küçük Resim
    Öğe
    Incidence and predictors of direct-acting antiviral treatment failure in Turkish patients with chronic hepatitis C genotype 1b infection
    (Sage Publications Inc, 2020) Cabalak, Mehmet; Bal, Tayibe; Onlen, Yusuf; Demir, Mehmet
    Evaluation of the incidence and predictors of failure of direct-acting antiviral treatment for hepatitis C virus genotype 1b patients is important. Our retrospective cohort study assessed 172 Turkish patients who had received a full course of such treatment and could be checked for sustained virologic response. The overall treatment failure rate was 2.9% (5/172), all of whom relapsed. In three of these cases with sequencing data available, all had NS5A resistance-associated substitution. Multivariate analysis revealed that a 1 mg/dL increase in pre-treatment total bilirubin level was associated with a sevenfold increased likelihood of treatment failure. The baseline level of total bilirubin was the only significant independent predictor of direct-acting antiviral treatment failure.
  • Küçük Resim
    Öğe
    The Investigation of Total PSA, Free PSA, and Free/Total PSA Ratio in Patients With Liver Cirrhosis Patients According to Child-Pugh Score
    (Elsevier Science Inc, 2013) Inci, Mehmet; Rifaioglu, Murat Mehmet; Inci, Melek; Celik, Murat; Demir, Mehmet; Ulutas, Turker; Davarci, Mursel
    OBJECTIVE To investigate the total prostate-specific antigen (tPSA), free PSA (fPSA), and free/total PSA (fPSA/tPSA) ratio in patients with liver cirrhosis (LC) according to the severity of hepatic insufficiency. METHODS Eighty-two male patients with LC were studied. The severity of liver disease was categorized by Child-Pugh score (Child-Pugh A, B, and C). Forty-two age-matched healthy subjects were used as a control group. The tPSA, fPSA, fPSA/tPSA ratio, total prostate volume (TPV), total testosterone (TT), and total protein (TP) were measured. The LC group was compared with the control group in terms of these parameters. In addition, intra-comparison and inter-comparison was made between all the Child-Pugh groups and normal subjects, in terms of these parameters. RESULTS The tPSA and fPSA levels in LC cases, Child-Pugh A, Child-Pugh B, and Child-Pugh C groups were significantly decreased compared with the control group. The ratio of fPSA/tPSA in the LC subjects and Child-Pugh A groups significantly increased compared with the control group. TT, TP levels, and TPV in patients with LC were significantly lower compared with the control group and the results were significantly correlated with the Child-Pugh score. CONCLUSION The present study reveals that tPSA and fPSA were decreased in patients with LC in comparison to healthy subjects in terms of 3 mechanisms. First, it might be due to shrunken prostatic volume. Second, it also resulted in decreased levels of testosterone because of the abnormality of hypothalamic-pituitary-testicular axis. Third, it might be the diminished serum protein level in the composition of the PSA. UROLOGY 81: 617-622, 2013. (c) 2013 Elsevier Inc.
  • Küçük Resim
    Öğe
    Is HMGB1 a New Indirect Marker for Revealing Fibrosis in Chronic Hepatitis and a New Therapeutic Target in Treatment?
    (Mary Ann Liebert, Inc, 2010) Albayrak, Ayse; Uyanik, Muhammet H.; Cerrah, Serkan; Altas, Sare; Dursun, Hakan; Demir, Mehmet; Uslu, Hakan
    In chronic hepatitis B virus (HBV) infection, inflammation-associated cytokines including proinflammatory cytokines are involved in the development and progression of liver fibrosis. The liver is a source of many cytokines that may influence liver function. High-mobility group box 1 (HMGB1) was identified as an inflammatory cytokine. HMGB1 is present in nuclei of all mammalian cells and is released both through active secretion from various cells and by passive release from necrotic cells. Here we explore the relationship between HMGB1 plasma levels and liver fibrosis. HMGB1 serum levels, HBV-DNA, and ALT values were significantly higher in patients with chronic HBV than in controls. In addition, HMGB1 serum levels were significantly higher in patients with low fibrosis (fibrosis score 1-2) compared to those with high fibrosis (fibrosis score 3-4). In the present study, we have shown that HMGB1 is a noninvasive, repeatable, and convenient marker for distinguishing advanced fibrosis from low fibrosis in chronic HBV patients. We believe that the inhibition of HMGB1 may reduce inflammation, apoptosis, and fibrosis, and may stop the progression of chronic liver disease. Furthermore, we are of the opinion that fibrotic progression in chronic liver patients may be prevented by the inhibition of HMGB1, and that this substance can be a new means of following chronic HBV treatment.
  • [ N/A ]
    Öğe
    Long-term clinical outcomes of Entecavir and .tenofovir in hepatitis B cirrhosis
    (Wiley-Blackwell, 2012) Koklu, Seyfettin; Tuna, Yasar; Gulsen, Murat T.; Demir, Mehmet; Koksal, Aydin S.; Kockar, Muhammed C.; Aygun, Cem
    [Abstract Not Available]
  • Küçük Resim
    Öğe
    Long-term Efficacy and Safety of Lamivudine, Entecavir, and Tenofovir for Treatment of Hepatitis B Virus-Related Cirrhosis
    (Elsevier Science Inc, 2013) Koklu, Seyfettin; Tuna, Yasar; Gulsen, Murat Taner; Demir, Mehmet; Koksal, Aydin Seref; Kockar, Muhammet Cem; Aygun, Cem
    BACKGROUND & AIMS: Data are limited on the efficacy and safety of tenofovir and entecavir when given for more than 1 year to patients with hepatitis B-related cirrhosis. We investigated the long-term safety and efficacy of these antiviral drugs in patients with chronic hepatitis B virus (HBV) infection, with compensated or decompensated cirrhosis, and compared results with those from lamivudine. METHODS: We performed a retrospective analysis of data from 227 adult patients with chronic HBV infection who were diagnosed with cirrhosis, beginning in 2005, at 18 centers throughout Turkey. There were 104 patients who had decompensated cirrhosis, and 197 patients were treatment naive before. Seventy-two patients received tenofovir (followed up for 21.4 +/- 9.7 mo), 77 patients received entecavir (followed up for 24.0 +/- 13.3 mo), and 74 patients received lamivudine (followed up for 36.5 +/- 24.1 mo). We collected data on patient demographics and baseline characteristics. Laboratory test results, clinical outcomes, and drug-related adverse events were compared among groups. RESULTS: Levels of HBV DNA less than 400 copies/mL were achieved in 91.5%, 92.5%, and 77% of patients receiving tenofovir, entecavir, or lamivudine, respectively. Levels of alanine aminotransferase normalized in 86.8%, 92.1%, and 71.8% of patients who received tenofovir, entecavir, and lamivudine, respectively. Child-Turcotte-Pugh scores increased among 8.5% of patients who received tenofovir, 15.6% who received entecavir, and 27.4% who received lamivudine. Frequencies of complications from cirrhosis, including hepatic encephalopathy, variceal bleeding, hepatocellular carcinoma, and mortality, were similar among groups. Lamivudine had to be changed to another drug for 32.4% of the patients. CONCLUSIONS: Tenofovir and entecavir are effective and safe for long-term use in patients with compensated or decompensated cirrhosis from HBV infection.